A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study

Publisher： John Wiley & Sons Inc

E-ISSN： 1463-1326|17|2|152-160

ISSN： 1462-8902

Source： DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.17, Iss.2, 2015-02, pp. : 152-160

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

By Seino Yutaka   Fujita Tetsuya   Hiroi Shinzo   Hirayama Masashi   Kaku Kohei  

Current Medical Research and Opinion, Vol. 27, Iss. 9, 2011-09 ,pp. : 1781-1792

Informa Healthcare

Access to resources Recommend Favorite

Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double‐blind, placebo‐controlled study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 3, 2015-03 ,pp. : 304-308

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study*

By Pratley Richard E.   Reusch Jane E.-B.   Fleck Penny R.   Wilson Craig A.   Mekki Qais  

Current Medical Research and Opinion, Vol. 25, Iss. 10, 2009-10 ,pp. : 2361-2371

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 453-457

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 530-540

John Wiley & Sons Inc

Access to resources Recommend Favorite